IPF News Briefs

Pulmonary fibrosis

USP13 May Play a Protective Role in Idiopathic Pulmonary Fibrosis

Researchers from China have identified ubiquitin-specific protease 13 (USP13) as a regulator of autophagy and age-related lung fibrosis in a mouse model. The results of their study were recently published in the American Journal of Respiratory Cell and Molecular Biology and contribute to current knowledge on the pathogenesis of idiopathic pulmonary fibrosis (IPF). “We hypothesize…

IPF diagnosis

New Study Aims to Investigate Potential RNA Interference Therapy for Treating IPF

Researchers will conduct a trial to study the efficacy of ARO-MMP7 inhalation solution in both healthy subjects and patients with idiopathic pulmonary fibrosis (IPF). The sponsor of this study is Arrowhead Pharmaceuticals. ARO-MMP7 is the company’s experimental RNA interference treatment that is designed to lower the expression of matrix metalloproteinase 7 (MMP7). MMP7 is a…

Idiopathic Pulmonary Fibrosis Drug Candidate Reduces Cough Frequency in Trial

Nalbuphine extended-release (ER) (Haduvio™), an investigational idiopathic pulmonary fibrosis (IPF) therapy, reduced the frequency of cough in a phase 2 clinical trial called CANAL. This finding is based on data from the full set of participants in the trial.  The results “are consistent with the previously announced interim analysis and further demonstrated that Haduvio has…

Deep learning illustration

Unsupervised Machine Learning Can Identify IPF Progression Markers

A new study has found that unsupervised machine learning is able to determine radiological disease progression markers in patients with idiopathic pulmonary fibrosis (IPF). The study, published in European Radiology, also observed pattern transitions that revealed a sequence of tissue types from healthy to advanced disease. “Besides the difficulties in diagnosing IPF, the prediction of…

IPF experimental therapies

Notch1 Signaling Significantly Contributes to ACE2 Fate in IPF

Researchers discovered that Notch1 signaling contributes to alveolar epithelial cells type II (ACE2) proliferation and dedifferentiation in patients with idiopathic pulmonary fibrosis (IPF). Their study was published in the American Journal of Respiratory and Critical Care Medicine.  “In the normal human lung, alveolar type II cells (ACE2) mostly exist in a highly differentiated state and…

lab test

Test May Help Avoid Potentially Harmful Treatments in Patients With IPF

The Envisia Genomic Classifier (EGC) can help identify patients with interstitial lung diseases (ILDs) whose disease is more likely to progress with combination immunosuppressive therapy, according to results presented at the European Respiratory Society (ERS) International Congress 2022.  This could assist physicians in making more informed decisions regarding treatment of these diseases, which include idiopathic…

data

Nonclinical Data Support BBT-301 and BBT-209 as Treatments for IPF

New nonclinical data on BBT-301, a novel small molecular KCa 3.1 inhibitor, and BBT-209, an endogenous GPCR19 agonist, show promise for the treatment of idiopathic pulmonary fibrosis (IPF), according to Bridge Biotherapeutics, which is developing both drugs. The results, announced by news release, were presented at the 6th Annual IPF Summit held recently in Boston,…

IPF

Pirfenidone Also Beneficial in Probable or Possible Idiopathic Pulmonary Fibrosis

Pirfenidone treatment leads to favorable outcomes in patients with probable or possible idiopathic pulmonary fibrosis (IPF), as it does in patients with definitive disease. These findings were reached in a European MultiPartner IPF Registry (EMPIRE) analysis published in PLoS One. Pirfenidone is widely used to treat patients with IPF. However, it is not known whether…

FDA sign

FDA Authorization Granted for Phase 2 Study of BBT-877 for IPF

The US Food and Drug Administration (FDA) has granted authorization to Bridge Biotherapeutics to carry out a phase 2 trial on BBT-877, an autotaxin inhibitor, for patients with idiopathic pulmonary fibrosis (IPF). The authorization, announced by news release, followed a Type C meeting with the FDA in June 2021 for the proceeding development of BBT-877,…

clinical research

New Study Testing Experimental Therapy for IPF Opens

A new clinical trial that aims to assess the efficacy of an investigational therapy for idiopathic pulmonary fibrosis (IPF) recently opened. The phase 2 participant- and investigator-blinded, randomized, placebo-controlled, multicenter study will include 94 patients with a diagnosis of IPF based on the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic…

Next post in IPF News Briefs